Doxycycline de prix la

Abstract

A randomized double-blind, placebo-controlled study, comparing intravenous diphosphate cycline (diphosphate monophosphate) (CP) with placebo, in the treatment of patients with community-acquired pneumonia, has demonstrated an efficacy of divalproate plus doxycycline (doxy) for the prevention of community-acquired pneumonia.

This randomized, double-blind, placebo-controlled trial has enrolled a total of 1750 patients, aged 18-65 years, who were randomized to divalproate (divalproate 600 mg/jour), placebo, and a single dose of doxycycline (doxy 250 mg/jour). The primary outcome was the incidence of community-acquired pneumonia (CP), secondary outcomes were the number of community-acquired pneumonia by day 5, and the length of hospital stay, defined as the time from admission to the visit.

Patients were randomized to the study group with a single dose of doxycycline (doxy 250 mg/jour) or placebo. The primary efficacy endpoints were the incidence of CP and the duration of the hospital stay.

For all patients in the divalproate-treated group, the primary efficacy endpoint was the mean number of CP by day 5. The primary efficacy endpoint was the mean length of hospital stay.

For patients in the doxycycline-treated group, the primary efficacy endpoint was the mean number of CP by day 5. The primary efficacy endpoint was the mean duration of hospital stay.

For patients in the divalproate-treated group, the primary efficacy endpoint was the mean number of CP.

The primary endpoints of this study were the incidence of CP, the mean number of CP, and the mean duration of hospital stay.

For patients in the doxycycline-treated group, the primary efficacy endpoint was the mean number of CP.

For patients in the divalproate-treated group, the primary efficacy endpoint was the mean duration of hospital stay.

For patients in the doxycycline-treated group, the primary efficacy endpoint was the mean number of CP.

For patients in the doxycycline-treated group, the primary efficacy endpoint was the mean number of CP.

The primary efficacy endpoints for this trial were the incidence of CP, the mean number of CP, and the mean duration of hospital stay.

The primary endpoints for this trial were the incidence of CP, the mean number of CP, and the mean duration of hospital stay.

The primary endpoints for this trial were the incidence of CP, the mean duration of hospital stay, and the mean length of hospital stay.

The primary endpoints for this trial were the incidence of CP, the mean number of CP, and the mean duration of hospital stay.

Publication types

MeSH terms